EGFR
EGFR (epidermal growth factor receptor) is the cell-surface receptor of its specific ligands, including epidermal growth factor and TGFα (transforming growth factor α) and is a receptor tyrosine kinase.
Products for EGFR
- Cat.No. Product Name Information
- GC15589 WHI-P154 A JAK3 inhibitor
- GC16000 WHI-P180 EGFR/Janus Kinase 3 inhibitor
- GC37933 WHI-P180 hydrochloride WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively.
- GC13213 WZ3146 Mutant EGFR inhibitor, potent and irreversible
- GC15494 WZ4002 Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent
- GC11250 WZ8040 EGFR T790M inhibitor,irreversible amd potent
-
GC70164
Zalutumumab
Zalutumumab is a highly affinity pure human IgG1 monoclonal antibody that targets EGFR. Zalutumumab binds to domain III of the epidermal growth factor receptor, exerting its effects by blocking the binding of epidermal growth factor and interfering with the receptor's active conformation. The EC50 values for Zalutumumab with IgG and its Fab regions are 7 and 19 nM, respectively. Zalutumumab can be used in cancer research.
-
GC70165
Zanidatamab
Zanidatamab (ZW25) is a human bispecific monoclonal antibody targeting 2 different HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumor activity.
- GC33171 ZD-4190 ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.
-
GC70169
Zenocutuzumab
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody that contains two different Fab arms targeting the extracellular domains of HER2 and HER3.